Events in January further encouraged such optimism, with KPMG's global life sciences chief declaring that “the signs are good for biotech deal activity in 2018”. With patents often at the heart of such transactions, a jump in deal-making would be a reason for IP professionals to feel cheerful about the year ...
Delivered by KPMG Today (@KPMG_TO)
Article continues here
Follow @KPMG_TO on Twitter to get latest updates
